Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1330Neoplasms 984Carcinoma, Non-Small-Cell Lung 860Prostatic Neoplasms 728Colorectal Neoplasms 665Lung Neoplasms 551Leukemia, Myeloid, Acute 476Neoplasm Metastasis 435Pancreatic Neoplasms 418Carcinoma, Hepatocellular 408Multiple Myeloma 396Ovarian Neoplasms 391Stomach Neoplasms 380Recurrence 364Squamous Cell Carcinoma of Head and Neck 324Melanoma 294Brain Neoplasms 289Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 273Glioblastoma 265Head and Neck Neoplasms 264Precursor Cell Lymphoblastic Leukemia-Lymphoma 255Endometrial Neoplasms 233Lymphoma 228Rectal Neoplasms 223Esophageal Neoplasms 222Sarcoma 214Carcinoma, Renal Cell 204Colonic Neoplasms 194Lymphoma, Non-Hodgkin 191

Interventions

eribulin 1disitamab vedotin 1RC48 antibody 1Paclitaxel 1Gemcitabine 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × HER2-low Breast Cancer × Clear all
NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
37 enrolled
Breast

HER2-low Breast Cancer

NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
566 enrolled
Breast

HER2-low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡